{"id":"W3028807982","doi":"10.1200/jco.2020.38.15_suppl.10500","title":"Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Vincristine; Irinotecan; Clinical endpoint; Refractory (planetary science); Internal medicine; Neuroblastoma; Vorinostat; Regimen; Phases of clinical research; Oncology; Randomized controlled trial; Clinical trial; Surgery; Urology; Chemotherapy; Cyclophosphamide; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004311189,0.002308371,0.00274467,0.0005943422,0.000535238,0.001237698,0.00131228,0.002433144,0.006796257],"category_scores_gemma":[0.002795679,0.0009152797,0.001781922,0.0005124217,0.001386046,0.001293775,0.0005320208,0.003789164,0.001255546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00118237,"about_ca_system_score_gemma":0.002080961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001127783,"about_ca_topic_score_gemma":0.00271441,"domain_scores_codex":[0.9985445,0.001087521,0.00005076375,0.0001478769,0.00004937362,0.0001201119],"domain_scores_gemma":[0.9980636,0.0006552346,0.0004432655,0.000136865,0.00009082956,0.0006101973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9794232,0.007034976,0.00048055,0.0002551395,0.000424354,0.00003694061,0.00004844557,0.0004674424,0.002880807,0.000117657,0.001015365,0.007815049],"study_design_scores_gemma":[0.9459029,0.05186385,0.0005946302,0.00001636859,0.0001768479,0.0000243527,0.00001396496,0.000442756,0.0003018799,0.0001293467,0.0005248249,0.000008345042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9723638,0.004816341,0.001499349,0.002363574,0.00101136,0.01217492,0.002483625,0.0002387482,0.003048313],"genre_scores_gemma":[0.9622159,0.002835014,0.005128087,0.00364013,0.001032596,0.01454703,0.003567069,0.00009363965,0.006940614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006796257,"threshold_uncertainty_score":0.02280003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4324664555464727,"score_gpt":0.4826815846230988,"score_spread":0.05021512907662617,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}